Skip to content

Performance of Imaging for the Diagnosis of Small Hepatocellular Carcinoma (< 3 cm)on Cirrhosis

Performance of Imaging for the Diagnosis of Small Hepatocellular Carcinoma (< 3 cm)on Cirrhosis

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00848952
Acronym
CHIC
Enrollment
450
Registered
2009-02-23
Start date
2009-03-31
Completion date
Unknown
Last updated
2010-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Brief summary

The purpose of this study is to evaluate 3 imaging techniques and their associations : MRI, CTscanner and enhanced contrast ultrasound for the diagnosis of small (\< 3 cm) hepatocellular carcinoma for patients with cirrhosis.

Detailed description

With the improvement of cirrhosis complications coverage, hepatocellular carcinoma (HCC) tend to become the main cause of mortality for cirrhotic patients. Currently, the incidence of the HCC increase in occidental country and hid global prognostic remain very bad. The main indication factor for a curative treatment is the size lesion. Cirrhosis is the main risk factor for HCC occurence. In France, HCC screening has been establish for cirrhotic patients with hepatic ultrasound and alfa-fetoprotein measurement with the aim of detected HCC when the size allows a curative treatment. When a nodule is discovered during the follow-up, HCC diagnosis is done following the recommendations of European Association for the Study of the Liver (AESL) in 2000, updated by the American Association for the Study of Liver Diseases (AASLD)in 2005. Diagnostic is function of nodule feature on one or two enhanced imaging techniques among CTscanner, MRI and enhanced contrast ultrasound. This diagnostic strategy raises several questions. First, neither the most efficient dynamic imaging association for nodules from 1 to 2 cm, nor the most efficient imaging examination for nodules from 2 to 3 cm are known. Second, only few studies have been carried out about imaging semiology of the small hepatocellular carcinoma. Thus, the imprecisions of the present recommendations regarding the choice of the best examination technique and the difficulties in the diagnosis of benign or malignant nature for small nodule can lead to a bad management of these patients.

Interventions

OTHER3 imaging techniques are done

all patients have : MRI, CTscanner, enhanced contrast ultrasound

Sponsors

University Hospital, Angers
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age \> 18 hears * presence of one or several nodules \< 3 cm * known or suspected cirrhosis

Exclusion criteria

* psychiatric disease * contraindication to one of the 3 imaging examinations (CTscanner, MRI, enhanced contrast ultrasound * patient already treated by chemoembolization * recurrence on the coagulation zone of a nodule already treated by per-cutaneous tumour destruction * presence of a tumour (\> 3 cm) associated to the nodule * pregnant woman or breast-feeding woman

Design outcomes

Primary

MeasureTime frame
Report of proportion of the positives truths and the positive wrong for an examinationone year

Countries

France

Contacts

Primary ContactChristophe Aube, professor
chaube@chu-angers.fr33-(0)2-41-35-42-81

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026